Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von PMLiVE

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
09.10.Ipsen's Iqirvo approved by MHRA to treat primary biliary cholangitis in adults
09.10.PMLiVE's T40 - results announced!
08.10.AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra
08.10.J&J's Erleada shows overall survival benefit in head-to-head prostate cancer study
08.10.ICR researchers reveal benefits of personalised radiotherapy for bladder cancer patients
07.10.AstraZeneca gains rights to CSPC's lipid-lowering therapy in deal worth over $1.9bn
07.10.AbbVie shares promising late-stage results for Parkinson's disease candidate tavapadon
07.10.ABPI highlights importance of NHS-industry partnerships in improving patient outcomes
04.10.Bristol Myers Squibb's Opdivo regimen granted FDA approval in NSCLC
04.10.Chiesi Group invests €400m to establish biotech centre of excellence in Italy
04.10.Researchers develop new approach to target cells affected by motor neurone disease
03.10.Eli Lilly announces new $4.5bn US site for manufacturing and drug development
03.10.GSK receives CHMP recommendation for meningococcal disease vaccine Menveo
03.10.NHS England begins newborn screening programme to identify rare genetic conditions
03.10.Results from Global Pharmaceutical Customer Experience survey
03.10.How patients are transforming cancer care: insights from ESMO on patient-centric oncology
03.10.Stats without stories: why journalists aren't covering your data
02.10.Sanofi/Regeneron's Dupixent approved by FDA to treat uncontrolled COPD
02.10.Roche's Genentech acquires Regor Pharmaceuticals' CDK inhibitors for $850m upfront
02.10.J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study
02.10.Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis
02.10.Strategy execution - ensuring it all fits together
01.10.Roche's injectable C5 inhibitor PiaSky recommended by NICE for rare blood disorder PNH
01.10.Johnson & Johnson's Yuvanci granted EC approval to treat pulmonary arterial hypertension
01.10.FDA approves IntraBio's Aqneursa to treat Niemann-Pick disease type C patients